Guided Therapeutics (GTHP) Cash from Operations Growth (1y) (2017 - 2026)
Guided Therapeutics (GTHP) Cash from Operations Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 21.54% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 13.50% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 14.62% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 124.64% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -11.16% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 78.72% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -0.23% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | -12.60% |
| 10 | Guided Therapeutics | 21.24 Mn | 21.23 Mn | - | -88.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -88.76% |
| Mar 31, 2026 | -86.40% |
| Dec 31, 2025 | 12.35% |
| Sep 30, 2025 | 41.44% |
| Jun 30, 2025 | 21.03% |
| Mar 31, 2025 | -231.00% |
| Dec 31, 2024 | 1.19% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | 51.14% |
| Mar 31, 2024 | 79.96% |
| Dec 31, 2023 | 0.88% |
| Sep 30, 2023 | 22.71% |
| Jun 30, 2023 | -25.50% |
| Mar 31, 2023 | -178.77% |
| Dec 31, 2022 | -313.21% |
| Sep 30, 2022 | 17.19% |
| Jun 30, 2022 | 49.57% |
| Mar 31, 2022 | 44.06% |
| Dec 31, 2021 | 148.04% |
| Sep 30, 2021 | -21.95% |